AJMB  Vol.4 No.2 , April 2014
Viscum Album Modulates Apoptotic Related Genes in Melanoma Tumor of Mice
Abstract: Cancer is a major public health problem throughout the world. It is estimated that one third of the American population will develop the disease at some time during their lifetimes. Among these, melanoma will account for 7% of the cases. In Brazil, in 2012, it is estimated that over six thousand new melanoma cases occurred. During recent years, the incidence of melanoma has increased, mainly due to a more constant exposure of the skin to sunlight. In this work, our aim is to assess the expression of apoptotis-related genes melanoma tumors in mice treated with Viscum album (VA). This will allow us to better understand the molecular mechanisms underlying tumor cell death activation caused by this compound. Our results clearly demonstrate upregulation of pro apoptotic genes (Trp53bp2, Nol3, Fadd, Tnfsf10, Traf1, Traf2, Cflar, Card10, Nod1, Casp 2, Casp7, Xiap, Dad1, and Dffb). Further bioinformatics-based tool analysis allowed us to assess which specific cell death-related intracellular pathways were activated by VA treatment. Two major effects of VA in melanoma cells could be observed: generation of an immunomudulatory Th-1 like action, recruiting several interleukines, and cell death activation through Caspase7, associated uspstream with Card10 and downstream with CAD. In summary, VA modulates apoptosis related genes in cancer melanoma cells. Although a deeper study should be conducted, VA seems to interfere with important signaling pathways within melanoma cells that control the cellular mechanisms of apoptosis activation. Therapeutic approaches using VA as an antineoplastic and adjuvant medication compounding should be considered.
Cite this paper: da Silva Facina, A. , Facina, G. , Guerreiro da Silva, I. , Aparecida Gonçalves, G. , Augusto de Almeida, F. , Aparecida Alves Corrêa de Noronha, S. , Marcos Ribeiro de Noronha, S. and Uchiyama Nakamura, M. (2014) Viscum Album Modulates Apoptotic Related Genes in Melanoma Tumor of Mice. American Journal of Molecular Biology, 4, 49-58. doi: 10.4236/ajmb.2014.42007.

[1]   Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012) Cancer Treatment and Survivorship Statistics. CA: A Cancer Journal for Clinicians, 62, 220-241.

[2]   Instituto Nacional de Cancer (2012) Estimativa 2012.

[3]   Bonfa, R., Bonamigo, R.R., Bonfa, R., Duro, K.M., Furian, R.D. and Zelmanowicz, A.M. (2011) Early Diagnosis of Cutaneous Melanoma: An Observation in Southern Brazil. Anais Brasileiros de Dermatologia, 86, 215-221.

[4]   NCCN Melanoma Practice Guidelines. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2013 Staging. Melanoma Table of Contents. Discussion. (2012) Ref Type: Internet Communication.

[5]   Eigentler, T.K., Caroli, U.M., Radny, P. and Garbe, C. (2003) Palliative Therapy of Disseminated Malignant Melanoma: A Systematic Review of 41 Randomised Clinical Trials. The Lancet Oncology, 4, 748-759.

[6]   Veronesi, U., Adamus, J., Aubert, C., Bajetta, E., Beretta, G., Bonadonna, G., et al. (1982) A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous Melanoma. The New England Journal of Medicine, 307, 913-916.

[7]   Molassiotis, A., Fernadez-Ortega, P., Pud D, Ozden G., Scott , J.A., Panteli, V., et al. (2005) Use of Complementary and Alternative Medicine in Cancer Patients: A European Survey. Annals of Oncology, 16, 655-663.

[8]   Laengler, A., Spix, C., Seifert, G., Gottschling, S., Graf, N. and Kaatsch, P. (2008) Complementary and Alternative Treatment Methods in Children with Cancer: A Population-Based Retrospective Survey on the Prevalence of Use in Germany. European Journal of Cancer, 44, 2233-2240.

[9]   Eustachi, A., Pajtler, H., Linde, K., Melchart, D. and Weidenhammer, W. (2009) Patients of an Interdisciplinary Cancer Treatment Center: Use of, Knowledge about, and Demand for CAM Treatment Options. Integrative Cancer Therapies, 8, 56-62.

[10]   Thies, A., Dautel, P., Meyer, A., Pfuller, U. and Schumacher, U. (2008) Low-Dose Mistletoe Lectin-I Reduces Melanoma Growth and Spread in a Scid Mouse Xenograft Model. British Journal of Cancer, 98, 106-112.

[11]   Kienle, G.S., Grugel, R. and Kiene, H. (2011) Safety of Higher Dosages of Viscum album L. in Animals and Humans—Systematic Review of Immune Changes and Safety Parameters. BMC Complementary and Alternative Medicine, 11, 72.

[12]   Kirsch, A. (2007) Successful Treatment of Metastatic Malignant Melanoma with Viscum album Extract (Iscador® M). The Journal of Alternative and Complementary Medicine, 13, 443-445.

[13]   Kienle, G.S., Berrino, F., Bussing, A., Portalupi, E., Rosenzweig, S. and Kiene, H. (2003) Mistletoe in Cancer—A Systematic Review on Controlled Clinical Trials. European Journal of Medical Research, 8, 109-119.

[14]   Horneber, M.A., Bueschel, G., Huber, R., Linde, K. and Rostock, M. (2008) Mistletoe Therapy in Oncology. Cochrane Database of Systematic Reviews, 2, Article ID: CD003297.

[15]   Khil, L.Y., Kim, W., Lyu, S., Park, W.B., Yoon, J.W. and Jun, H.S. (2007) Mechanisms Involved in Korean Mistletoe Lectin-Induced Apoptosis of Cancer Cells. World Journal of Gastroenterology, 13, 2811-2818.

[16]   Lyu, S.Y. and Park, W.B. (2006). Mistletoe Lectin (Viscum album Coloratum) Modulates Proliferation and Cytokine Expressions in Murine Splenocytes. BMB Reports, 39, 662-670.

[17]   Seifert, G., Jesse, P., Laengler, A., Reindl, T., Luth, M., Lobitz, S., et al. (2008) Molecular Mechanisms of Mistletoe Plant Extract-Induced Apoptosis in Acute Lymphoblastic Leukemia in Vivo and in Vitro. Cancer Letters, 264, 218-228.

[18]   Van Huyen, J.P., Delignat, S., Bayry, J., Kazatchkine, M.D., Bruneval, P., Nicoletti, A., et al. (2006) Interleukin-12 Is Associated with the in Vivo Anti-Tumor Effect of Mistletoe Extracts in B16 Mouse Melanoma. Cancer Letters, 243, 32-37.

[19]   Hegde, P., Maddur, M.S., Friboulet, A., Bayry, J. and Kaveri, S.V. (2011) Viscum album Exerts Anti-Inflammatory Effect by Selectively Inhibiting Cytokine-Induced Expression of Cyclooxygenase-2. PLoS One, 6, e26312.

[20]   Podlech, O., Harter, P.N., Mittelbronn, M., Poschel, S. and Naumann, U. (2012) Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas. Evidence-Based Complementary and Alternative Medicine, 2012, Article ID: 501796.

[21]   Hamsa, T.P. and Kuttan, G. (2011) Harmine Activates Intrinsic and Extrinsic Pathways of Apoptosis in B16F-10 Melanoma. Chinese Medicine, 6, 11.

[22]   Ramnath, V., Rekha, P.S., Kuttan, G. and Kuttan, R. (2009) Regulation of Caspase-3 and Bcl-2 Expression in Dalton’s Lymphoma Ascites Cells by Abrin. Evidence-Based Complementary and Alternative Medicine, 6, 233-238.

[23]   Miyashita, T. and Reed, J.C. (1995) Tumor Suppressor p53 Is a Direct Transcriptional Activator of the Human Bax Gene. Cell, 80, 293-299.

[24]   Trigiante, G. and Lu, X. (2006) ASPP [Corrected] and Cancer. Nature Reviews Cancer, 6, 217-226.

[25]   Ao, J.E., Kuang, L.H., Zhou, Y., Zhao, R., Yang, C.M. (2012) Hypoxia-Inducible Factor 1 Regulated ARC Expression Mediated Hypoxia Induced Inactivation of the Intrinsic Death Pathway in p53 Deficient Human Colon Cancer Cells. Biochemical and Biophysical Research Communications, 420, 913-917.

[26]   Wilson, N.S., Dixit, V. and Ashkenazi, A. (2009) Death Receptor Signal Transducers: Nodes of Coordination in Immune Signaling Networks. Nature Immunology, 10, 348-355.

[27]   Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M. and Goeddel, D.V. (1995) The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins. Cell, 83, 1243-1252.

[28]   Guicciardi, M.E., Mott, J.L., Bronk, S.F., Kurita, S., Fingas, C.D. and Gores, G.J. (2011) Cellular Inhibitor of Apoptosis 1 (cIAP-1) Degradation by Caspase 8 during TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis. Experimental Cell Research, 317, 107-116.

[29]   Sprick, M.R. and Walczak, H. (2004) The Interplay between the Bcl-2 Family and Death Receptor-Mediated Apoptosis. Biochimica et Biophysica Acta, 1644, 125-132.

[30]   McLornan, D., Hay, J., McLaughlin, K., Holohan, C., Burnett, A.K., Hills, R.K., et al. (2012) Prognostic and Therapeutic Relevance of c-FLIP in Acute Myeloid Leukaemia. British Journal of Haematology, 16, 188-198.

[31]   Miura, K., Fujibuchi, W. and Unno, M. (2012) Splice Variants in Apoptotic Pathway. Experimental Oncology, 34, 212-217.

[32]   Nam, Y.J., Mani, K., Ashton, A.W., Peng, C.F., Krishnamurthy, B., Hayakawa, Y., et al. (2004) Inhibition of Both the Extrinsic and Intrinsic Death Pathways through Nonhomotypic Death-Fold Interactions. Molecular Cell, 15, 901-912.

[33]   Narayanan, S., Surolia, A. and Karande, A.A. (2004) Ribosome-Inactivating Protein and Apoptosis: Abrin Causes Cell Death via Mitochondrial Pathway in Jurkat Cells. Biochemical Journal, 377, 233-240.

[34]   Elmore, S. (2007) Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology, 35, 495-516.

[35]   Kamiya, T., Okabayashi, T., Yokota, S., Kan, Y., Ogino, J., Yamashita, T., et al. (2010) Increased Caspase-2 Activity Is Associated with Induction of Apoptosis in IFN-Beta Sensitive Melanoma Cell Lines. Journal of Interferon & Cytokine Research, 30, 349-357.

[36]   Robertson, J.D., Enoksson, M., Suomela, M., Zhivotovsky, B. and Orrenius, S. (2002) Caspase-2 Acts Upstream of Mitochondria to Promote Cytochrome c Release during Etoposide-Induced Apoptosis. The Journal of Biological Chemistry, 277, 29803-29809.

[37]   Manon, F., Favier, A., Nunez, G., Simorre, J.P. and Cusack, S. (2007) Solution Structure of NOD1 CARD and Mutational Analysis of Its Interaction with the CARD of Downstream Kinase RICK. Journal of Molecular Biology, 365, 160-174.

[38]   Hong, G.S. and Jung, Y.K. (2002) Caspase Recruitment Domain (CARD) as a Bi-Functional Switch of Caspase Regulation and NF-kappaB Signals. Journal of Biochemistry and Molecular Biology, 35, 19-23.

[39]   Lamkanfi, M., Kanneganti, T.D., Van, D.P., Vanden, B.T., Vanoverberghe, I., Vandekerckhove, J., et al. (2008) Targeted Peptidecentric Proteomics Reveals Caspase-7 as a Substrate of the Caspase-1 Inflammasomes. Molecular & Cellular Proteomics, 7, 2350-2363.

[40]   Lamkanfi, M. and Kanneganti, T.D. (2010) Caspase-7: A Protease Involved in Apoptosis and Inflammation. The International Journal of Biochemistry & Cell Biology, 42, 21-24.

[41]   Hamsa, T.P. and Kuttan, G. (2010) Harmine Inhibits Tumour Specific Neo-Vessel Formation by Regulating VEGF, MMP, TIMP and Pro-Inflammatory Mediators Both in Vivo and in Vitro. European Journal of Pharmacology, 649, 64-73.

[42]   Bratton, S.B., Walker, G., Srinivasula, S.M., Sun, X.M., Butterworth, M., Alnemri, E.S., et al. (2001) Recruitment, Activation and Retention of Caspases-9 and -3 by Apaf-1 Apoptosome and Associated XIAP Complexes. The EMBO Journal, 20, 998-1009.

[43]   Eckelman, B.P. and Salvesen, G.S. (2006) The Human Anti-Apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases. Journal of Biological Chemistry, 281, 3254-3260.

[44]   Lindholm, P., Kuittinen, T., Sorri, O., Guo, D., Merits, A., Tormakangas, K., et al. (2000) Glycosylation of Phytepsin and Expression of dad1, dad2 and ost1 during Onset of Cell Death in Germinating Barley Scutella. Mechanisms of Development, 93, 169-173.

[45]   Ter-Minassian, M., Wang, Z., Asomaning, K., Wu, M.C., Liu, C.Y., Paulus, J.K., et al. (2011) Genetic Associations with Sporadic Neuroendocrine Tumor Risk. Carcinogenesis, 32, 1216-1222.

[46]   Xiao, F., Widlak, P. and Garrard, W.T. (2007) Engineered Apoptotic Nucleases for Chromatin Research. Nucleic Acids Research, 35, e93.

[47]   Kim, B.E., Lee, Y.H., Seong, C., Shin, S.Y., Lee, J.S., Cho, B.Y., et al. (2005) Salt Is Necessary for Nucleosomal DNA Fragmentation Induced by Caspase. Biotechnology Letters, 27, 1935-1942.